GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascentage Pharma Group International (HKSE:06855) » Definitions » Enterprise Value

Ascentage Pharma Group International (HKSE:06855) Enterprise Value : HK$8,584.6 Mil (As of Jun. 23, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Ascentage Pharma Group International Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Ascentage Pharma Group International's Enterprise Value is HK$8,584.6 Mil. Ascentage Pharma Group International's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-915.3 Mil. Therefore, Ascentage Pharma Group International's EV-to-EBIT ratio for today is -9.38.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Ascentage Pharma Group International's Enterprise Value is HK$8,584.6 Mil. Ascentage Pharma Group International's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-885.9 Mil. Therefore, Ascentage Pharma Group International's EV-to-EBITDA ratio for today is -9.69.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Ascentage Pharma Group International's Enterprise Value is HK$8,584.6 Mil. Ascentage Pharma Group International's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$242.8 Mil. Therefore, Ascentage Pharma Group International's EV-to-Revenue ratio for today is 35.36.


Ascentage Pharma Group International Enterprise Value Historical Data

The historical data trend for Ascentage Pharma Group International's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascentage Pharma Group International Enterprise Value Chart

Ascentage Pharma Group International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial 5,402.34 8,223.14 6,650.90 7,169.38 8,727.96

Ascentage Pharma Group International Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,650.90 5,455.07 7,169.38 6,229.60 8,727.96

Competitive Comparison of Ascentage Pharma Group International's Enterprise Value

For the Biotechnology subindustry, Ascentage Pharma Group International's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ascentage Pharma Group International's Enterprise Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Ascentage Pharma Group International's Enterprise Value falls into.



Ascentage Pharma Group International Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Ascentage Pharma Group International's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Ascentage Pharma Group International's Enterprise Value for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ascentage Pharma Group International  (HKSE:06855) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Ascentage Pharma Group International's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=8584.577/-915.28
=-9.38

Ascentage Pharma Group International's current Enterprise Value is HK$8,584.6 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Ascentage Pharma Group International's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-915.3 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Ascentage Pharma Group International's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=8584.577/-885.9
=-9.69

Ascentage Pharma Group International's current Enterprise Value is HK$8,584.6 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Ascentage Pharma Group International's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-885.9 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Ascentage Pharma Group International's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=8584.577/242.802
=35.36

Ascentage Pharma Group International's current Enterprise Value is HK$8,584.6 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Ascentage Pharma Group International's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$242.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ascentage Pharma Group International Enterprise Value Related Terms

Thank you for viewing the detailed overview of Ascentage Pharma Group International's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Ascentage Pharma Group International (HKSE:06855) Business Description

Traded in Other Exchanges
Address
68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company's geographical segments include the United States and Mainland China.
Executives
Ascentage Limited
Gao Sharon Xia
Guo Edward Ming
Healthquest Pharma Limited
Li Ju-yun
Wang Shaomeng
Yang Dajun
Zhai Yifan
South Dakota Trust Company Llc 2301 Trustee
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Tian Yuan 2201 Interest of corporation controlled by you
Zhao Li 2202 Interest of your spouse
Xian Jin Zhi Zao Chan Ye Tou Zi Ji Jin You Xian He Huo 2201 Interest of corporation controlled by you
Xian Jin Zhi Zao Chan Ye Tou Zi You Xian Gong Si 2101 Beneficial owner
Guo Tou Chuang Xin Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you

Ascentage Pharma Group International (HKSE:06855) Headlines

No Headlines